6. Glycemic Targets: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
Diabetes care, 2025 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials
M Dambrova, M Makrecka-Kuka, J Kuka… - Pharmacological …, 2022 - ASPET
Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy
metabolism pathways. They have historically been used as important diagnostic markers for …
metabolism pathways. They have historically been used as important diagnostic markers for …
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a …
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association - Diabetes care, 2021 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
Type 1 diabetes
Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and
resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past …
resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past …
[HTML][HTML] Nutrition therapy for adults with diabetes or prediabetes: a consensus report
AB Evert, M Dennison, CD Gardner, WT Garvey… - Diabetes …, 2019 - ncbi.nlm.nih.gov
This Consensus Report is intended to provide clinical professionals with evidencebased
guidance about individualizing nutrition therapy for adults with diabetes or prediabetes …
guidance about individualizing nutrition therapy for adults with diabetes or prediabetes …
[HTML][HTML] Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
A Rawshani, A Rawshani, S Franzén… - New England journal …, 2018 - Mass Medical Soc
Background Patients with diabetes are at higher risk for death and cardiovascular outcomes
than the general population. We investigated whether the excess risk of death and …
than the general population. We investigated whether the excess risk of death and …
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetologia, 2018 - Springer
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …
Diabetes convened a panel to update the prior position statements, published in 2012 and …